PRMT5 and B-cell chronic lymphocytic leukemia: PRT382 demonstrated in vitro and in vivo efficacy against CLL cell lines, isolated CLL patient cells, and the CLL-like cells from the Eμ-PRMT5/TCL1 mouse model of CLL/RT, overall providing strong evidence supporting the use of targeted PRMT5 inhibition in CLL with elevated PRMT5 expression at high risk of RT.